Risankizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Stephen K. Tyring
Phoebe Rich
Yayoi Tada
Stefan Beeck
Izabella Messina
Jie Liu
Xiaohong Huang
Stephen Shumack
机构：
[1] University of Texas Health Science Center,Department of Dermatology, McGovern Medical School
[2] Oregon Health and Science University,undefined
[3] Teikyo University School of Medicine,undefined
[4] AbbVie Inc.,undefined
[5] St George Dermatology and Skin Cancer Centre,undefined
来源：
Dermatology and Therapy | 2023年 / 13卷
关键词：
Atopic dermatitis; Interleukin-23; Risankizumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：595 / 608
页数：13
相关论文
共 50 条
  • [41] Summary of Research: An Anti-OX40 Antibody to Treat Moderate-to-Severe Atopic Dermatitis: A Multicentre, Double-Blind, Placebo-Controlled Phase 2b Study
    Guttman-Yassky, Emma
    Simpson, Eric L.
    Reich, Kristian
    Kabashima, Kenji
    Igawa, Ken
    Suzuki, Tetsuya
    Mano, Hirotaka
    Matsui, Takeshi
    Esfandiari, Ehsanollah
    Furue, Masutaka
    ADVANCES IN THERAPY, 2024, 41 (03) : 928 - 931
  • [42] Efficacy, safety and pharmacology of oral ASN002, a novel Jak/Syk inhibitor, in moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Guttman-Yassky, N. A.
    Maari, N. A.
    Forman, N. A.
    Bhatia, N. A.
    Lee, N. A.
    Fowler, N. A.
    Tyring, N. A.
    Pariser, N. A.
    Sofen, N. A.
    Dhawan, N. A.
    Zook, N. A.
    Estrada, N. A.
    Pavel, N. A.
    Zammit, J.
    Sarper, N. A.
    Rao, N. A.
    Bissonnette, N. A.
    BRITISH JOURNAL OF DERMATOLOGY, 2018, 179 (01) : E40 - E41
  • [43] Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study
    Feagan, Brian G.
    Sandborn, William J.
    D'Haens, Geert
    Panes, Julian
    Kaser, Arthur
    Ferrante, Marc
    Louis, Edouard
    Franchimont, Denis
    Dewit, Olivier
    Seidler, Ursula
    Kim, Kyung-Jo
    Neurath, Markus F.
    Schreiber, Stefan
    Scholl, Paul
    Pamulapati, Chandrasena
    Lalovic, Bojan
    Visvanathan, Sudha
    Padula, Steven J.
    Herichova, Ivona
    Soaita, Adina
    Hall, David B.
    Bocher, Wulf O.
    LANCET, 2017, 389 (10080): : 1699 - 1709
  • [44] Effect of memantine combination therapy on symptoms in patients with moderate-to-severe depressive disorder: randomized, double-blind, placebo-controlled study
    Amidfar, M.
    Khiabany, M.
    Kohi, A.
    Salardini, E.
    Arbabi, M.
    Azizi, M. Roohi
    Zarrindast, M. -R.
    Mohammadinejad, P.
    Zeinoddini, A.
    Akhondzadeh, S.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2017, 42 (01) : 44 - 50
  • [45] Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial
    Silverberg, J. I.
    Toth, D.
    Bieber, T.
    Alexis, A. F.
    Elewski, B. E.
    Pink, A. E.
    Hijnen, D.
    Jensen, T. N.
    Bang, B.
    Olsen, C. K.
    Kurbasic, A.
    Weidinger, S.
    BRITISH JOURNAL OF DERMATOLOGY, 2021, 184 (03) : 450 - 463
  • [46] Fecal microbiota transplantation against moderate-to-severe atopic dermatitis: A randomized, double-blind controlled explorer trial
    Liu, Xiaochun
    Luo, Yang
    Chen, Xingyu
    Wu, Mingyang
    Xu, Xiaoqiang
    Tian, Jingru
    Gao, Yingxia
    Zhu, Jun
    Wang, Zhifeng
    Zhou, Yuan
    Zhang, Yu
    Wang, Xiaokai
    Li, Wei
    Lu, Qianjin
    Yao, Xu
    ALLERGY, 2024,
  • [47] Efficacy of Probiotics in Children and Adolescents With Atopic Dermatitis: A Randomized, Double-Blind, Placebo-Controlled Study
    Andrade, Paula Danielle Santa Maria Albuquerque de
    Silva, Jorgete
    Carregaro, Vanessa
    Sacramento, Lais Amorim
    Roberti, Luciana Rodrigues
    Aragon, Davi Casale
    Carmona, Fabio
    Roxo-Junior, Persio
    FRONTIERS IN NUTRITION, 2022, 8
  • [48] Efficacy and safety of lebrikizumab combined with topical corticosteroids in Japanese patients with moderate-to-severe atopic dermatitis: a phase 3, double-blind, placebo-controlled, randomized clinical trial (ADhere-J)
    Katoh, Norito
    Tanaka, Akio
    Takahashi, Hidetoshi
    Shimizu, Ryosuke
    Kataoka, Yoko
    Torisu-Itakura, Hitoe
    Morisaki, Yoji
    Igawa, Ken
    CURRENT MEDICAL RESEARCH AND OPINION, 2025, 41 (01) : 1 - 12
  • [49] Rapid improvement in skin pain, and its impact on quality of life, in adult patients with moderate-to-severe atopic dermatitis from a double-blind, placebo-controlled baricitinib phase 3 study
    Rosmarin, David
    Fretzin, Scott
    Strowd, Lindsay
    Casillas, Marta
    DeLozier, Amy
    Dawson, Zach
    Chen, Sherry
    Lu, Na
    Thyssen, Jacob P.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB96 - AB96
  • [50] Effects of abrocitinib on pruritus and eczema symptoms and tolerance in patients with moderate-to-severe atopic dermatitis in randomized, double-blind and placebo-controlled trials: A systematic review and a meta-analysis
    Xie, Xingxing
    Zhang, Jie
    Huang, Fujing
    Fan, Ling
    BIOMEDICAL REPORTS, 2024, 20 (05)
12345